Skip to main
APYX

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical Corp has shown significant revenue growth in its Surgical Aesthetics segment, with expectations of reaching $43.0 million to $45.0 million, marking a 14.0% year-over-year increase at the midpoint. The overall full-year revenue guidance has been raised to between $50.5 million and $52.5 million, driven primarily by improved execution and demand trends in the Surgical Aesthetics segment. Additionally, the company is anticipating enhanced revenue contributions from the AYON launch, as sales for the quarter rose to $12.9 million, reflecting a 12% increase compared to the previous year, underscoring the positive market reception and growth potential in this sector.

Bears say

Apyx Medical Corp has experienced a decline in projected OEM sales, now forecasted at approximately $7.5 million, down from prior expectations of $8.0 million, which highlights reduced sales volumes to existing customers. Additionally, the company has faced significant operational challenges, including the lingering effects of an FDA warning letter issued in March 2022 and market pressures related to the increased use of GLP-1 medications, impacting demand in the aesthetics sector. Furthermore, Apyx Medical’s cash and cash equivalents decreased from $29.3 million at the end of Q2 2025 to $25.1 million at the end of Q3 2025, indicating potential liquidity concerns amid a volatile revenue environment heavily reliant on its Surgical Aesthetics segment.

APYX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Strong Buy based on their latest research and market trends.

According to 4 analysts, APYX has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.